Trial to Determine Effective Aspirin Dose in COPD
Randomized Trial to Determine Effective Aspirin Dose in COPD
Sponsor: Johns Hopkins University
Listed as NCT05265299, this PHASE3 trial focuses on Pulmonary Disease, Chronic Obstructive and remains actively recruiting participants. Sponsored by Johns Hopkins University, it has been updated 10 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jun 2023 — Apr 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 5 earlier versions
-
Apr 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .